Foghorn Therapeutics Inc. FHTX

FHTX Company Overview

Foghorn Therapeutics Inc. is a U.S.-based biotechnology company focused on developing precision medicines that target the chromatin regulatory system, a network of proteins that controls gene expression and is frequently disrupted in cancer. The company operates within the oncology and genomic medicine sectors and uses its proprietary Gene Traffic Control platform to identify and develop therapies aimed at genetically defined cancers. Its primary revenue sources have included research collaborations, licensing arrangements, and funding associated with strategic partnerships, while its long-term business model centers on the commercialization of targeted oncology therapeutics.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn was established by scientists and biotechnology executives seeking to apply discoveries in chromatin biology to cancer treatment. The company has evolved from an early-stage discovery platform into a clinical-stage biotechnology enterprise with multiple investigational programs focused on chromatin remodeling complexes and transcriptional regulation. Foghorn’s positioning is differentiated by its focus on the therapeutic targeting of the chromatin regulatory system, an area historically viewed as difficult to drug but increasingly recognized as clinically actionable.